Table 2 Detailed treatment and MGFA evaluation during disease course of MuSK MG patients
From: Spotlight on MuSK positive myasthenia gravis: clinical characteristics, treatment and outcomes
N | Gender | Age at onset (years) | Duration (days) | MGFA classification | Treatment | ||
|---|---|---|---|---|---|---|---|
PYR | CS | T acro | |||||
(1) OMG patients | |||||||
1 | female | 48 | 0 | I | N | N | N |
30 | IIb, GEb | N | N | N | |||
82 | NA | Y | Y | N | |||
87 | V, MC | Y(240 mg) | Y(45 mg) | N | |||
360 | IIa | Y(120 mg) | Y(10 mg) | N | |||
2 | male | 71 | 0 | I | N | N | N |
150 | IIIb, GE | NA | N | N | |||
260 | NA | Y | Y | N | |||
350 | V, MC | Y(360 mg) | Y(60 mg) | N | |||
380 | died | ||||||
3 | female | 50 | 0 | I | N | N | N |
76 | IIb, GE | N | Y | N | |||
95 | I | N | Y(80 mg) | N | |||
300 | 0* | N | N | N | |||
1020 | 0 | N | N | N | |||
4 | female | 37 | 0 | I | N | N | N |
25 | I | Y(180 mg) | N | N | |||
74 | I | Y(270 mg) | Y(60 mg) | N | |||
180 | Ia | Y(360 mg) | Y(40 mg) | N | |||
210 | IIb, GE | Y(180 mg) | Y(30 mg) | Y | |||
306 | 0 | Y(90 mg) | Y(25 mg) | Y | |||
5 | female | 31 | 0 | I | N | N | N |
180 | IIb, GE | N | N | N | |||
385 | IIb | N | N | N | |||
393 | NA | N | Y | N | |||
565 | IIb | Y(180 mg) | Y(60 mg) | N | |||
1105 | 0* | N | N | N | |||
2903 | 0 | N | N | N | |||
6 | female | 40 | 0 | I | N | N | N |
120 | IIb, GE | N | N | N | |||
502 | NA | Y | Y | N | |||
521 | IIb | Y(240 mg) | Y(52 mg) | Y | |||
1855 | IIb | N | N | N | |||
7 | female | 49 | 0 | I | N | N | N |
30 | NA | Y | Y | N | |||
270 | IIIb, GE | Y | Y | N | |||
279 | V, MC | Y(240 mg) | Y(20 mg) | N | |||
510 | IIIb | Y(480 mg) | Y(48 mg) | N | |||
860 | 0 | N | Y(15 mg) | N | |||
8 | female | 59 | 0 | I | N | N | N |
60 | IIa, GE | N | N | N | |||
146 | NA | Y | Y | N | |||
1610 | I | Y(180 mg) | N | Y | |||
2240 | I | N | N | Y | |||
2810 | IIb | N | Y(56 mg) | Y | |||
3440 | IIIb | N | Y(60 mg) | N | |||
3762 | IIa | N | Y(15 mg) | N | |||
9 | male | 57 | 0 | I | N | N | N |
157 | IIa, GE | N | Y | Y | |||
226 | I | N | Y(48 mg) | Y | |||
325 | I | Y(30 mg) | Y(30 mg) | Y | |||
10 | female | 57 | 0 | I | N | N | N |
60 | IIIb, GE | N | Y | N | |||
259 | V, MCa | N | Y(45 mg) | N | |||
630 | died | ||||||
(2) BMG patients | |||||||
11 | female | 50 | 0 | IIb | N | N | N |
270 | IIb | Y(90 mg) | N | N | |||
420 | 0* | N | N | N | |||
12 | female^ | 66 | 0 | IIb | N | N | N |
25 | IIb | Y | Y | N | |||
40 | IIb | Y(180 mg) | Y(10 mg) | N | |||
13 | female | 36 | 0 | IIIb | N | N | N |
20 | NA | Y | Y | N | |||
50 | V, MC | Y(360 mg) | Y(40 mg) | N | |||
750 | IIIb | Y(180 mg) | Y(50 mg) | N | |||
1255 | 0 | N | Y(20 mg) | Y | |||
14 | female | 63 | 0 | IIb | N | N | N |
371 | V,MC# | Y | Y | N | |||
380 | IIIb | Y(180 mg) | Y(50 mg) | N | |||
1320 | 0 | Y(60 mg) | Y(15 mg) | N | |||
15 | male | 75 | 0 | IIIb | N | N | N |
192 | NA | Y | Y | N | |||
198 | IIIb | Y(180 mg) | Y(60 mg) | N | |||
543 | 0 | Y(180 mg) | Y(15 mg) | N | |||
16 | female | 68 | 0 | IIb | N | N | N |
1065 | NA | Y | Y | Y | |||
1490 | IIb | Y(180 mg) | Y(50 mg) | Y | |||
2525 | 0 | Y(60 mg) | Y(10 mg) | Y | |||
17 | female^ | 16 | 0 | IIb | N | N | N |
216 | NA | Y | Y | N | |||
223 | IIb | Y(180 mg) | Y(50 mg) | N | |||
230 | IIb | Y(180 mg) | Y(50 mg) | N | |||
18 | female | 30 | 0 | IIb | N | N | N |
18 | NA | N | Y | N | |||
36 | IIb | N | Y(50 mg) | N | |||
840 | IIa | N | Y(50 mg) | N | |||
910 | IIa | N | N | N | |||
19 | female | 78 | 0 | IIb | N | N | N |
366 | NA | Y | Y | N | |||
370 | IIb | Y(180 mg) | Y(20 mg) | N | |||
1170 | IIb | Y(180 mg) | Y(20 mg) | N | |||
(3) GMG patients | |||||||
20 | male^ | 61 | 0 | IIa | NA | N | N |
21 | female | 47 | 0 | IIa | N | N | N |
206 | NA | Y | Y | N | |||
210 | IIb | Y(240 mg) | Y(60 mg) | N | |||
1095 | IIa | Y(60 mg) | Y(20 mg) | N | |||